|
||||||
|
 | Fusion Gene Summary |
| Fusion Gene ORF analysis |
| Fusion Genomic Features |
| Fusion Protein Features |
| Fusion Gene Sequence |
| Fusion Gene PPI analysis |
| Related Drugs |
| Related Diseases |
Fusion gene:CDK12-LGALS9 (FusionGDB2 ID:HG51755TG3965) |
Fusion Gene Summary for CDK12-LGALS9 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: CDK12-LGALS9 | Fusion gene ID: hg51755tg3965 | Hgene | Tgene | Gene symbol | CDK12 | LGALS9 | Gene ID | 51755 | 3965 |
| Gene name | cyclin dependent kinase 12 | galectin 9 | |
| Synonyms | CRK7|CRKR|CRKRS | HUAT|LGALS9A | |
| Cytomap | ('CDK12')('LGALS9') 17q12 | 17q11.2 | |
| Type of gene | protein-coding | protein-coding | |
| Description | cyclin-dependent kinase 12CDC2-related protein kinase 7Cdc2-related kinase, arginine/serine-richcell division cycle 2-related protein kinase 7cell division protein kinase 12 | galectin-9ecalectingal-9lectin, galactoside-binding, soluble, 9tumor antigen HOM-HD-21urate transporter/channel protein | |
| Modification date | 20200313 | 20200315 | |
| UniProtAcc | . | O00182 | |
| Ensembl transtripts involved in fusion gene | ENST00000430627, ENST00000447079, ENST00000559545, | ||
| Fusion gene scores | * DoF score | 29 X 13 X 13=4901 | 8 X 8 X 5=320 |
| # samples | 31 | 9 | |
| ** MAII score | log2(31/4901*10)=-3.98273602613552 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | log2(9/320*10)=-1.83007499855769 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: CDK12 [Title/Abstract] AND LGALS9 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Most frequent breakpoint | CDK12(37657692)-LGALS9(25965288), # samples:1 | ||
| Anticipated loss of major functional domain due to fusion event. | CDK12-LGALS9 seems lost the major protein functional domain in Hgene partner, which is a CGC due to the frame-shifted ORF. CDK12-LGALS9 seems lost the major protein functional domain in Hgene partner, which is a essential gene due to the frame-shifted ORF. CDK12-LGALS9 seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF. CDK12-LGALS9 seems lost the major protein functional domain in Hgene partner, which is a kinase due to the frame-shifted ORF. | ||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Hgene | CDK12 | GO:0046777 | protein autophosphorylation | 11683387 |
| Tgene | LGALS9 | GO:0006954 | inflammatory response | 23817958 |
| Tgene | LGALS9 | GO:0007565 | female pregnancy | 23242525 |
| Tgene | LGALS9 | GO:0010628 | positive regulation of gene expression | 16116184 |
| Tgene | LGALS9 | GO:0010629 | negative regulation of gene expression | 23408620 |
| Tgene | LGALS9 | GO:0032673 | regulation of interleukin-4 production | 16116184 |
| Tgene | LGALS9 | GO:0032674 | regulation of interleukin-5 production | 16116184 |
| Tgene | LGALS9 | GO:0032689 | negative regulation of interferon-gamma production | 23408620 |
| Tgene | LGALS9 | GO:0032753 | positive regulation of interleukin-4 production | 20209097 |
| Tgene | LGALS9 | GO:0032834 | positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation involved in immune response | 20209097 |
| Tgene | LGALS9 | GO:0034134 | toll-like receptor 2 signaling pathway | 16116184 |
| Tgene | LGALS9 | GO:0034142 | toll-like receptor 4 signaling pathway | 16116184 |
| Tgene | LGALS9 | GO:0038066 | p38MAPK cascade | 16116184 |
| Tgene | LGALS9 | GO:0045953 | negative regulation of natural killer cell mediated cytotoxicity | 23408620 |
| Tgene | LGALS9 | GO:0046598 | positive regulation of viral entry into host cell | 21670307 |
| Tgene | LGALS9 | GO:0050718 | positive regulation of interleukin-1 beta secretion | 20209097 |
| Tgene | LGALS9 | GO:0060135 | maternal process involved in female pregnancy | 25578313 |
| Tgene | LGALS9 | GO:0070241 | positive regulation of activated T cell autonomous cell death | 20209097 |
| Tgene | LGALS9 | GO:0070371 | ERK1 and ERK2 cascade | 16116184 |
| Tgene | LGALS9 | GO:0070555 | response to interleukin-1 | 23817958 |
| Tgene | LGALS9 | GO:0071346 | cellular response to interferon-gamma | 23817958 |
| Tgene | LGALS9 | GO:0071636 | positive regulation of transforming growth factor beta production | 20209097 |
| Tgene | LGALS9 | GO:1902715 | positive regulation of interferon-gamma secretion | 20209097 |
| Tgene | LGALS9 | GO:1904469 | positive regulation of tumor necrosis factor secretion | 20209097 |
| Tgene | LGALS9 | GO:2000562 | negative regulation of CD4-positive, alpha-beta T cell proliferation | 20209097 |
| Tgene | LGALS9 | GO:2000563 | positive regulation of CD4-positive, alpha-beta T cell proliferation | 16116184 |
| Tgene | LGALS9 | GO:2000667 | positive regulation of interleukin-13 secretion | 20209097 |
| Tgene | LGALS9 | GO:2000670 | positive regulation of dendritic cell apoptotic process | 16116184 |
| Tgene | LGALS9 | GO:2001181 | positive regulation of interleukin-10 secretion | 16116184|20209097 |
| Tgene | LGALS9 | GO:2001190 | positive regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell | 16116184 |
| Fusion gene information * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Source | Disease | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| ChimerDB4 | COAD | TCGA-AZ-6600 | CDK12 | chr17 | 37657692 | + | LGALS9 | chr17 | 25965288 | + |
Top |
Fusion Gene ORF analysis for CDK12-LGALS9 |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5CDS-3UTR | ENST00000430627 | ENST00000448970 | CDK12 | chr17 | 37657692 | + | LGALS9 | chr17 | 25965288 | + |
| 5CDS-3UTR | ENST00000447079 | ENST00000448970 | CDK12 | chr17 | 37657692 | + | LGALS9 | chr17 | 25965288 | + |
| 5CDS-5UTR | ENST00000430627 | ENST00000413914 | CDK12 | chr17 | 37657692 | + | LGALS9 | chr17 | 25965288 | + |
| 5CDS-5UTR | ENST00000447079 | ENST00000413914 | CDK12 | chr17 | 37657692 | + | LGALS9 | chr17 | 25965288 | + |
| Frame-shift | ENST00000430627 | ENST00000302228 | CDK12 | chr17 | 37657692 | + | LGALS9 | chr17 | 25965288 | + |
| Frame-shift | ENST00000430627 | ENST00000310394 | CDK12 | chr17 | 37657692 | + | LGALS9 | chr17 | 25965288 | + |
| Frame-shift | ENST00000430627 | ENST00000313648 | CDK12 | chr17 | 37657692 | + | LGALS9 | chr17 | 25965288 | + |
| Frame-shift | ENST00000430627 | ENST00000395473 | CDK12 | chr17 | 37657692 | + | LGALS9 | chr17 | 25965288 | + |
| Frame-shift | ENST00000447079 | ENST00000302228 | CDK12 | chr17 | 37657692 | + | LGALS9 | chr17 | 25965288 | + |
| Frame-shift | ENST00000447079 | ENST00000310394 | CDK12 | chr17 | 37657692 | + | LGALS9 | chr17 | 25965288 | + |
| Frame-shift | ENST00000447079 | ENST00000313648 | CDK12 | chr17 | 37657692 | + | LGALS9 | chr17 | 25965288 | + |
| Frame-shift | ENST00000447079 | ENST00000395473 | CDK12 | chr17 | 37657692 | + | LGALS9 | chr17 | 25965288 | + |
| intron-3CDS | ENST00000559545 | ENST00000302228 | CDK12 | chr17 | 37657692 | + | LGALS9 | chr17 | 25965288 | + |
| intron-3CDS | ENST00000559545 | ENST00000310394 | CDK12 | chr17 | 37657692 | + | LGALS9 | chr17 | 25965288 | + |
| intron-3CDS | ENST00000559545 | ENST00000313648 | CDK12 | chr17 | 37657692 | + | LGALS9 | chr17 | 25965288 | + |
| intron-3CDS | ENST00000559545 | ENST00000395473 | CDK12 | chr17 | 37657692 | + | LGALS9 | chr17 | 25965288 | + |
| intron-3UTR | ENST00000559545 | ENST00000448970 | CDK12 | chr17 | 37657692 | + | LGALS9 | chr17 | 25965288 | + |
| intron-5UTR | ENST00000559545 | ENST00000413914 | CDK12 | chr17 | 37657692 | + | LGALS9 | chr17 | 25965288 | + |
| ORFfinder result based on the fusion transcript sequence of in-frame fusion genes. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | Seq length (transcript) | BP loci (transcript) | Predicted start (transcript) | Predicted stop (transcript) | Seq length (amino acids) |
| DeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated. |
| Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | No-coding score | Coding score |
Top |
Fusion Genomic Features for CDK12-LGALS9 |
| FusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints. |
| Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand | 1-p | p (fusion gene breakpoint) |
| CDK12 | chr17 | 37657692 | + | LGALS9 | chr17 | 25965288 | + | 3.55E-07 | 0.99999964 |
| CDK12 | chr17 | 37657692 | + | LGALS9 | chr17 | 25965288 | + | 3.55E-07 | 0.99999964 |
| Distribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page. |
 |
Top |
Fusion Protein Features for CDK12-LGALS9 |
| Four levels of functional features of fusion genes Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/:37657692/:25965288) - FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels. - How to search 1. Put your fusion gene symbol. 2. Press the tab key until there will be shown the breakpoint information filled. 4. Go down and press 'Search' tab twice. 4. Go down to have the hyperlink of the search result. 5. Click the hyperlink. 6. See the FGviewer result for your fusion gene. |
 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| . | LGALS9 |
| FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}. | FUNCTION: Binds galactosides (PubMed:18005988). Has high affinity for the Forssman pentasaccharide (PubMed:18005988). Ligand for HAVCR2/TIM3 (PubMed:16286920). Binding to HAVCR2 induces T-helper type 1 lymphocyte (Th1) death (PubMed:16286920). Also stimulates bactericidal activity in infected macrophages by causing macrophage activation and IL1B secretion which restricts intracellular bacterial growth (By similarity). Ligand for P4HB; the interaction retains P4HB at the cell surface of Th2 T-helper cells, increasing disulfide reductase activity at the plasma membrane, altering the plasma membrane redox state and enhancing cell migration (PubMed:21670307). Ligand for CD44; the interaction enhances binding of SMAD3 to the FOXP3 promoter, leading to up-regulation of FOXP3 expression and increased induced regulatory T (iTreg) cell stability and suppressive function (By similarity). Promotes ability of mesenchymal stromal cells to suppress T-cell proliferation (PubMed:23817958). Expands regulatory T-cells and induces cytotoxic T-cell apoptosis following virus infection (PubMed:20209097). Activates ERK1/2 phosphorylation inducing cytokine (IL-6, IL-8, IL-12) and chemokine (CCL2) production in mast and dendritic cells (PubMed:24465902, PubMed:16116184). Inhibits degranulation and induces apoptosis of mast cells (PubMed:24465902). Induces maturation and migration of dendritic cells (PubMed:25754930, PubMed:16116184). Inhibits natural killer (NK) cell function (PubMed:23408620). Can transform NK cell phenotype from peripheral to decidual during pregnancy (PubMed:25578313). Astrocyte derived galectin-9 enhances microglial TNF production (By similarity). May play a role in thymocyte-epithelial interactions relevant to the biology of the thymus. May provide the molecular basis for urate flux across cell membranes, allowing urate that is formed during purine metabolism to efflux from cells and serving as an electrogenic transporter that plays an important role in renal and gastrointestinal urate excretion (By similarity). Highly selective to the anion urate (By similarity). {ECO:0000250|UniProtKB:O08573, ECO:0000250|UniProtKB:P97840, ECO:0000269|PubMed:16116184, ECO:0000269|PubMed:16286920, ECO:0000269|PubMed:18005988, ECO:0000269|PubMed:18977853, ECO:0000269|PubMed:20209097, ECO:0000269|PubMed:21670307, ECO:0000269|PubMed:23408620, ECO:0000269|PubMed:23817958, ECO:0000269|PubMed:24465902, ECO:0000269|PubMed:25578313, ECO:0000269|PubMed:25754930}.; FUNCTION: [Isoform 2]: Acts as an eosinophil chemoattractant (PubMed:9642261). It also inhibits angiogenesis (PubMed:24333696). Suppresses IFNG production by natural killer cells (By similarity). {ECO:0000250|UniProtKB:O08573, ECO:0000269|PubMed:24333696, ECO:0000269|PubMed:9642261}. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
Fusion Gene Sequence for CDK12-LGALS9 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones. |
Top |
Fusion Gene PPI Analysis for CDK12-LGALS9 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
Related Drugs for CDK12-LGALS9 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.8 2021-05-08) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
Top |
Related Diseases for CDK12-LGALS9 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | CDK12 | C0033578 | Prostatic Neoplasms | 1 | CTD_human |
| Hgene | CDK12 | C0376358 | Malignant neoplasm of prostate | 1 | CTD_human |
| Tgene | C0027697 | Nephritis | 1 | CTD_human |
Copyright 2021-Present -The University of Texas Health Science Center at Houston (UTHealth)
Web File Viewing | Emergency Information |Campus Carry|Site Policies